Publisher : The Korea Academia-Industrial cooperation Society
DOI : 10.5762/KAIS.2016.17.1.152
Title & Authors
Inhibitory Effects of Human Glutamate Dehydrogenase Isozymes by Antipsychotic Drugs for Schizophrenia Nam, A-Reum; Kim, In-Sik; Yang, Seung-Ju;
Glutamate is one of the major excitatory neurotransmitters in the central nervous system of vertebrates. Human GDH (hGDH) is the enzyme that regulates the glutamate metabolism and its expression is higher in the brains of schizophrenia patients than in normal subjects. This study examined the changes in the hGDH enzymatic activity caused by antipsychotic drugs (haloperidol, risperidone, ()-sulpride, chlopromazine hydrochloride, melperone, ()butaclamol, domperidone, clozapine) related to schizophrenia. First of all, hGDH isozymes (hGDH1, hGDH2) were synthesized by genetic recombination. As a result of the enzyme assay, haloperidol, ()-sulpride, melperone and clozapine had an inhibitory effect on the hGDH isozymes. In addition, haloperidol showed a non-competitive inhibition against the substrate, 2-oxoglutarate. In contrast, it showed an uncompetitive inhibition against another substrate, NADH. The inhibitory effect of haloperidol on hGDH2 was abolished by the presence of L-leucine, an allosteric effector of hGDH, but by not other antipsychotic drugs. These results revealed the inhibition of enzyme activity by psychotropic drugs in hGDH isoenzymes (hGDH1 and hGDH2) and the possibility that haloperidol may be used to regulate the GDH activity and glutamate concentration in the central nervous system.
Perez SM, Lodge DJ. New approaches to the management of schizophrenia: focus on aberrant hippocampal drive of dopamine pathways. Drug Design, Development and Therapy. 8:887-896, 2014.
Valencia M, Fresan A, Barak Y, Juarez F, Escamilla R, Saracco R. Predicting functional remission in patients with schizophrenia: a cross-sectional study of symptomatic remission, psycho-social remission, functioning, and clinical outcome. Neuropsychiatric Disease and Treatment. 11:2339-2348, 2015. DOI: http://dx.doi.org/10.2147/NDT.S87335
McGrath J, Saha S, Welham J, El Saadi O, MacCauley C, Chant D. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Med. 2:13, 2004. DOI: http://dx.doi.org/10.1186/1741-7015-2-13
Stilo SA, Murray RM. The epidemiology of schizophrenia: replacing dogma with knowledge. Dialogues Clin Neurosci. 12:305-315, 2010.
Nitin Gogtay, Nora S. Vyas, Renee Testa, Stephen J. Wood, and Christos Pantelis Age of Onset of Schizophrenia: Perspectives From Structural Neuroimaging Studies Schizophr Bull 37 (3): 504-513, 2011. DOI: http://dx.doi.org/10.1093/schbul/sbr030
Jiyeon Kwak, Yangmi Kim. The effect of anti psychotics and antidepressants on the TREK2 channel. Journal of the Korea Academia-Industrial cooperation Society, 13:5:2125-2132, 2012.
Rauser, L., Savage, J. E., Meltzer, H. Y., & Roth, B. L. Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine2C receptor. Journal of Pharmacology and Experimental Therapeutics, 299(1), 83-89, 2001.
Haris, M., Nath, K., Cai, K., Singh, A., Crescenzi, R., Kogan, F., & Reddy, R. Imaging of glutamate neurotransmitter alterations in Alzheimer's disease. NMR in biomedicine, 26(4), 386-391, 2013. DOI: http://dx.doi.org/10.1002/nbm.2875
Javitt, D.C. Glutamate and schizophrenia: Phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions. Int. Rev. Neurobiol. 78:69-108, 2007. DOI: http://dx.doi.org/10.1016/j.schres.2006.11.024
Beasley, C. L., Pennington, K., Behan, A., Wait, R., Dunn, M. J., Cotter, D. Proteomic analysis of the anterior cingulate cortex in the major psychiatric disorders: Evidence for disease-associated changes. Proteomics. 6:3414-3425, 2006. DOI: http://dx.doi.org/10.1002/pmic.200500069
Plaitakis, A, and Shashidharan, P. Glutamate transport and metabolism in dopaminergic neurons of substantia nigra: implications for the pathogenesis of Parkinson's disease. J. Neurol. 247 Suppl 2, II25-II35, 2000. DOI: http://dx.doi.org/10.1007/PL00007757
C Anthony Altar, Marquis P Vawter and Stephen D Ginsberg. Target Identification for CNS Diseases by Transcriptional Profiling. Neuropsychopharmacology 34, 18-54, 2009. DOI: http://dx.doi.org/10.1038/npp.2008.172
Spanaki C, Zaganas I, Kleopa KA, Plaitakis A. Human GLUD2 Glutamate Dehydrogenase Is Expressed in Neural and Testicular Supporting Cells. The Journal of Biological Chemistry. 285(22):16748-16756. 2010. DOI: http://dx.doi.org/10.1074/jbc.M109.092999
Cavallaro, S., D'Agata, V., Manickam, P., Dufour, F., & Alkon, D. L. Memory-specific temporal profiles of gene expression in the hippocampus. Proceedings of the National Academy of Sciences, 99(25), 16279-16284, 2002. DOI: http://dx.doi.org/10.1073/pnas.242597199
Yang, S. J., Huh, J. W., Hong, H. N., Kim, T. U., & Cho, S. W. Important role of Ser443 in different thermal stability of human glutamate dehydrogenase isozymes. FEBS letters, 562(1), 59-64, 2004. DOI: http://dx.doi.org/10.1016/S0014-5793(04)00183-8
Choi, M.M., Kim, E.A., Huh, J.W., Choi, S.Y., Cho, S.W., Yang, S.J. siRNA mediated silencing of human glutamate dehydrogenase induces apoptosis in neuroblastoma cells. Biotechnol Appl Biochem. 51, 107-110, 2008. DOI: http://dx.doi.org/10.1042/BA20070190
Myung-Min Choi, Jae-Wan Huh, Seung-Ju Yang, Eun Hee Cho, Soo Young Choi, Sung-Woo Cho, Identification of ADP-ribosylation site in human glutamate dehydrogenase isozymes, FEBS Letters, vol. 579, no. 19, pp. 4125-4130, 2005.
Seung-Ju Yang, Jae-Wan Huh, Hea-Nam Hong, Tae Ue Kim, Sung-Woo Cho, Important role of Ser443 in different thermal stability of human glutamate dehydrogenase isozymes 1, FEBS Letters, Vol. 562, no. 3, pp. 59-64, 2004.
Choi, M., Kim, E., Choi, S. Y., Kim, T. U., Cho, S., & Yang, S. Inhibitory properties of nerve-specific human glutamate dehydrogenase isozyme by chloroquine. Journal of biochemistry and molecular biology, 40(6), 1077, 2007. DOI: http://dx.doi.org/10.5483/BMBRep.2007.40.6.1077